NOTRELOAD AI
  • NOTRELOAD AI
  • XYZ.
  • XY.
  • #TrumpTrade
  • Discord
  • Buy Me a Coffee →
Sign in Subscribe

This post is for paying subscribers only

Already have an account? Sign in.

Oscar Health Navigates Q2 Loss, Targets 2026 Profitability

Oscar Health's Q2 2025 showed a $228M loss due to sicker patients. CEO Mark Bertolini aims for 2026 profitability.

08/06/2025 · 6:36 AM
OSCR
/ Read more

Feed↓

Breast Cancer Cells
Featured/ 09/05/2025 · 9:26 AM

BioNTech's Trastuzumab Pamirtecan Achieves Phase 3 Success for HER2-Positive Breast Cancer

BioNTech's new "smart bomb" cancer drug, trastuzumab pamirtecan, excelled in trials for HER2+ breast cancer, beating an older therapy. This marks BioNTech's first major oncology success and offers a promising new option for patients, globally.

/ Subscriber only
09/05/2025 · 8:18 AM

CERo Therapeutics: AML Drug Gains FDA Fast Track

CERo's AML drug, CER-1236, received FDA Fast Track & Orphan Drug status and is in a Phase 1/1b trial. CERo Therapeutics faces a Nasdaq delisting challenge due to low stockholders' equity, but has appealed and plans to raise funds.

/ Subscriber only
09/05/2025 · 7:58 AM

CG Oncology's Cretostimogene: Durable Response in High-Risk Bladder Cancer

Cretostimogene, a new bladder cancer treatment, shows durable 24-month complete responses (41.8%) in high-risk patients unresponsive to BCG. It has a good safety profile and offers bladder-sparing potential, with approval submission planned.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Buy Me a Coffee
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe